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Abstract
Background Two pharmacokinetic/pharmacodynamic studies were conducted to evaluate the potential drug–drug interaction
between elagolix, an oral gonadotropin-releasing hormone receptor antagonist, and an oral contraceptive (ethinylestradiol
[EE] 0.035 mg and norgestimate 0.18/0.215/0.25 mg) or progestin-only contraceptive (norethindrone 0.35 mg) in healthy
premenopausal women.
Methods These phase I studies used a two-period, sequential design, where period 1 included treatment with oral contraceptives, followed by period 2 with contraceptives coadministered with elagolix 150 mg once daily.
Results In study 1, pharmacokinetic exposures for EE in period 2 increased by 30% and the norgestimate metabolites
decreased by approximately 15% when coadministered with elagolix. Mean hormone exposure appeared lower for folliclestimulating hormone (FSH; 31%), luteinizing hormone (LH; 38%), and estradiol (E2; 16%). The percentage of women with
consecutive progesterone (P) concentrations above 5 nmol/L was similar in both periods. Norethindrone pharmacokinetic
exposures were comparable in both periods. The hormone exposure for LH and FSH was similar, and mean E2 exposure
was 32% lower in period 2. The percentage of subjects with consecutive ovulatory P concentrations was also similar in both
periods (study 2). Safety and tolerability profiles were unremarkable in both studies.
Conclusions Coadministration of elagolix 150 mg once daily with oral contraceptives containing EE and norgestimate, or
norethindrone, resulted in small pharmacokinetic changes in the oral contraceptive components. Similar or lower FSH, LH,
and E2 exposures were observed during coadministration, with ovulatory P concentrations also comparable in both periods.
The pharmacodynamic profiles of the oral contraceptives were maintained when coadministered with elagolix.
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1 Introduction
Elagolix, a novel, non-peptide, oral, short-acting competitive gonadotropin-releasing hormone receptor antagonist,
was approved by the US FDA in 2018 for the management
of moderate-to-severe pain associated with endometriosis
[1]. Treatment with elagolix in women with endometriosisassociated pain has provided benefits with reductions in
dysmenorrhea, non-menstrual pelvic pain, and dyspareunia
[2], as well as improvements in workplace and household
productivity [3, 4]. Elagolix pharmacokinetic (PK) and
pharmacodynamic (PD) studies have shown dose-dependent
suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), estradiol (E2), and progesterone (P),
as well as suppression of ovulation [5–8].
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Key Points
Small changes in the pharmacokinetics of oral contraceptives were observed when coadministered with
elagolix 150 mg once daily.
Based on the assessments of luteinizing hormone,
follicle-stimulating hormone, estradiol, and ovulatory
progesterone concentrations, the coadministration of oral
contraceptives with elagolix 150 mg once daily does not
appear to lessen the hormone pharmacodynamics of the
oral contraceptives.

Elagolix is not a contraceptive and effective methods of
birth control should be used while taking elagolix. In addition, the elagolix product label states that its efficacy may be
reduced in women taking estrogen-containing contraceptives
[1]. As women are still looking for effective birth control
options while receiving treatment for endometriosis, it is
important to evaluate whether elagolix may be coadministered with hormonal contraceptives from a PK/PD and tolerability perspective.
Combination oral contraceptives (COCs) and progestinonly (mini-pill) contraceptives are two effective means of
hormonal contraception and are options for women treated
with elagolix. The main mechanism for these hormonal
contraceptives is to inhibit ovulation through inhibiting the
pituitary production and secretion of FSH and LH [9]. Two
studies were conducted to evaluate the potential drug–drug
interaction (DDI) between elagolix and COCs or the minipill and the impact of coadministration with elagolix on PK
and PD, as well as the effects on safety and tolerability.

2 Methods
The studies were conducted in accordance with the protocol
and guidelines governing clinical study conduct and ethical
principles that have their origin in the Declaration of Helsinki. Institutional Review Board approval was obtained
at each of the five sites (Schulman Associates IRB, Inc.,
Cincinnati, OH, USA). All women signed informed consent
forms before participating.

2.1 Study Design
Two separate phase I, multiple-dose, open-label studies
were conducted according to a two-period, sequential design

with healthy premenopausal women (Fig. 1). In study 1, all
women received COC pills with doses of ethinylestradiol
(EE; 0.035 mg) and norgestimate (0.18/0.215/0.25 mg) for
≥ 3 months prior to study start (day 1). Period 1 consisted of
28 days of women continuing their existing regimen. During
period 2 (days 29–84), women received a COC and elagolix
150 mg tablet once daily; this elagolix dose was one of the
doses (150 mg once daily and 200 mg twice daily) evaluated
in phase III trials. In study 2, women received a norethindrone 0.35 mg tablet once daily (a progestin-only contraceptive) for period 1; those who were naïve to the mini-pill had
a 1-month lead-in. The same treatment pattern was followed
as in study 1.
Women self-administered the study drug(s) throughout
the treatment period. At each visit, women were counseled
on medication adherence and appropriate and effective use
of dual non-hormonal contraception. Women were followed
until the resumption of menses or 60 days, whichever came
first.

2.2 Inclusion/Exclusion Criteria
The following criteria apply to both studies. Subjects were
required to be healthy premenopausal females aged between
18 and 49 years, inclusive; have a history of regular menstrual cycles prior to initial study drug administration; have
a negative serum and urine pregnancy test; body mass index
(BMI) 18–35 kg/m2; and in general good health based on
the results of a medical history, physical examination, vital
signs, laboratory profile, and 12-lead electrocardiogram.
Subjects were excluded if they were < 6 months postpartum, post-abortion, post-pregnancy, or post-lactation;
pregnant or breast feeding; were using hormonal medication
other than the specified oral contraceptive; were using any
known inhibitors or inducers of cytochrome P450 enzyme
3A (CYP3A), P-glycoprotein (P-gp) inhibitors within 1
month prior; and had a history of ovarian cysts, polycystic
ovarian syndrome, oophorectomy, or hysterectomy. The hormonal therapies, known inducers/inhibitors of CYP3A, and
inhibitors of P-gp were not to be taken during the screening,
treatment, or follow-up periods of either study.

2.3 Pharmacokinetic/Pharmacodynamic Sampling
For intensive 24-h PK sampling for both studies, women
remained at the study site during period 1 (oral contraceptives alone) and period 2 (oral contraceptives + elagolix).
Blood samples for PK analysis {EE, metabolites of norgestimate (norelgestromin [NGMN], norgestrel [NG]), norethindrone, elagolix} were collected by venipuncture at the
following time points: prior to dosing, and 0.5, 1, 1.5, 2,
3, 4, 6, 8, 10, 12, 16, and 24 h after dosing (days indicated
in Fig. 1). The steady-state PK sampling of norgestimate
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Fig. 1  Study design and procedure notes. a Study 1; b Study
2. QD once daily, PK pharmacokinetics

metabolites were taken when a norgestimate dose of 0.25
mg was administered in both periods.
Blood samples for PD analysis (FSH, LH, E2, and P)
were collected by venipuncture once weekly for study 1 and
twice weekly on non-consecutive days for study 2. During
intensive PK days, PD samples were collected predose and
24 h after dosing.
Samples quantified below the lowest standard were
reported as zero.
2.3.1 Pharmacokinetic Sample Analysis
EE, metabolites of norgestimate, norethindrone, and elagolix
blood samples were collected in potassium (K2) ethylenediaminetetraacetic acid (EDTA)-containing collection tubes.
The blood samples were centrifuged using a refrigerated

centrifuge (1100–1300 g for approximately 10 min) within
60 min of collection to separate the plasma. The plasma
samples were placed in the freezer within 2 h after collection
and maintained at − 70 °C until shipped to AbbVie.
The elagolix, EE, NGMN, and NG plasma assays were
performed by the Drug Analysis Department of AbbVie,
North Chicago, IL, USA. Plasma concentrations of EE,
NGMN, NG, norethindrone, and elagolix [5] were determined using a validated liquid chromatography method
with tandem mass spectrometric detection (LC–MS/MS).
The samples were analyzed by subject. The lower limits of
quantitation (LLOQs) for EE, NGMN, and NG and norethindrone were established at 0.00247 ng/mL, 0.0198 ng/
mL, and 0.0203 ng/mL and 0.0936 ng/mL, respectively.
The LLOQ for elagolix was established at 0.126 ng/mL for
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standard range A (0.126–196 ng/mL) and 1.57 ng/mL for
standard range B (1.57–2460 ng/mL).
2.3.2 Pharmacodynamic Samples
Serum hormone concentrations (E2, P, LH, FSH) were
measured using College of American Pathologist (CAP)/
Clinical Laboratory Improvement Amendments (CLIA)
assay methods at a central laboratory (Quest Diagnostics
Nichols Institute, Valencia, CA, USA). LH and FSH were
measured using the immunoassay methods, and E2 and P
were measured using the LC–MS/MS methods. The LLOQ
values were 0.5 IU/L for FSH, 0.2 IU/L for LH, 2 pg/mL for
E2, and 0.32 nmol/L for P.

2.4 Statistical Analysis
2.4.1 Pharmacokinetics
The maximum observed plasma concentration (Cmax) and
time to Cmax (peak time, Tmax), as well as the terminal phase
elimination half-life and area under the plasma concentration–time curve (AUC) over the 24-h dosing interval (AUC
24) were estimated for EE, NGMN, NG, norethindrone, and
elagolix. Parameters were calculated using Phoenix™ WinNonlin® version 6.3 (Pharsight Corporation, Mountain
View, CA, USA) for both studies. Each woman served as
their own control. A repeated measures analysis of variance
(ANOVA) was performed to compare the PK of coadministration and oral contraceptives administered alone. The
model included a fixed effect for regimen (oral contraceptive
alone and oral contraceptives coadministered with elagolix);
subjects were viewed as a random effect. Cmax and AUC
were analyzed on the logarithmic scale. Within the framework of ANOVA, the relative bioavailability assessments
with point estimate and 90% confidence interval (CI) were
provided for the ratios of EE, NGMN, NG, and norethindrone Cmax and AUC, to compare the coadministration of
oral contraceptives with elagolix, versus alone.

analysis. Additionally, the percentage of subjects with two
consecutive P concentrations above 5 nmol/L were counted
and assessed as markers for ovulation and compared between
periods 1 and 2 [7].
2.4.3 Sample Size Calculations
For study 1, study size consideration was based on a comparison between day 21 (COC alone) and day 77 (COC in
combination with elagolix) within the crossover ANOVA
framework. Complete data from 26 subjects would provide
approximately 80% power to detect the minimum detectable
differences in AUC24/Cmax for NGMN, NG, and EE.
For study 2, study size consideration was based on a
comparison between day 7 (norethindrone alone) and day
63 (norethindrone in combination with elagolix) within the
crossover ANOVA framework. Complete data from 26 subjects would provide approximately 82% power to detect a
23% difference in the central value of norethindrone trough
concentrations (Ctrough) between day 63 and day 7. The
power calculations were performed using logarithmic transformation. The calculation assumed the error term variance
of 0.0967 for the natural logarithm of Ctrough.
Both studies planned to enroll 30 subjects to provide
allowance for premature discontinuations, assuming a dropout rate of approximately 10%.

2.5 Safety and Tolerability
For both studies, adverse event (AE) monitoring and vital
signs, physical examination, electrocardiogram, and laboratory test assessments were performed. Subjects who received
at least one dose of study medication were included in the
safety analyses. AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 15.0.
The number and percentage of women having treatmentemergent AEs (TEAEs) were tabulated by primary System
Organ Class and MedDRA Preferred Term.

2.4.2 Pharmacodynamics

3 Results

Mean + standard deviation (SD) E2, P, LH, and FSH levels were descriptively summarized in graphical format. In
order to compare the overall concentrations and exposures
for FSH and LH and E2 in both periods, the AUC values
over period 1 on days 1–28 (AUC1–28 days) and period 2 on
days 57–84 (AUC57–84 days) were calculated using Phoenix™
WinNonlin® version 6.3 (Pharsight Corporation) for both
studies. The mean hormone AUC values were calculated and
compared between period 1 (days 1–28) and period 2 (days
57–84). Subjects who had the last PD samples collected
before day 84 were excluded from E2, FSH, and LH AUC

3.1 Subject Dispositions
In study 1, 32 women were enrolled and 22 women completed the study. One woman was enrolled but was not dosed
(positive drug screen). Nine women prematurely discontinued: exclusionary medication (1), abnormal pap test (1), positive pregnancy test (1), AE of headache (1), and withdrew
consent (5). Of note, the woman with a positive urine pregnancy test only received one dose of COC on day 1 of period
1; screening serum and urine pregnancy tests were negative.
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The analyses included 21 women for PK (one woman missed
the intensive PK visit), 22 for PD, and 31 for safety.
In study 2, 34 women were enrolled and 26 women completed the study. Eight women prematurely discontinued
for the following reasons: AEs of increased triglycerides (2,
twin sisters) and hemoglobin decreased (1), positive drug
Table 1  Summary of demographic characteristics for studies 1 and 2
Characteristic

Study 1 (n = 31)

Study 2 (n = 34)

Age, years
Weight, kg
Height, cm
Race [n (%)]

31.0 ± 6.5 (20–43)
66.5 ± 16.0 (44–106)
161.4 ± 7.1 (150–175)
26 White (83.9)
5 Black (16.1)

36.4 ± 8.5 (20–50)a
65.6 ± 12.8 (37–100)
160.9 ± 6.1 (150–175)
28 White (82.4)
6 Black (17.6)

Data are expressed as mean ± standard deviation (minimum–maximum) unless otherwise specified
a

Two subjects were 49 years of age at the time consent was signed.
All subjects were female
Table 2  Pharmacokinetic
parameters of ethinylestradiol/
NGMN/NG and elagolix in
periods 1 and 2

Pharmacokinetic
parameters (units)

Ethinylestradiol
Cmax (ng/mL)
Tmax (h)
AUC24 (ng·h/mL)
t½a,b (h)
NGMN
Cmax (ng/mL)
Tmax (h)
AUC24 (ng·h/mL)
t½a (h)
NG
Cmax (ng/mL)
Tmax (h)
AUC24 (ng·h/mL)
t½a,d (h)
Elagolix
Cmax (ng/mL)
Tmax (h)
AUC24 (ng·h/mL)
t½a,d (h)

screen (1), non-compliance (1), and withdrew consent (3).
The analyses included 26 women for PK and PD, and 34
for safety.
Table 1 summarizes the demographic characteristics.

4 Pharmacokinetics
In study 1, the PK parameters of EE, NGMN, and NG are
presented in Table 2 and concentration–time profiles are
presented in Fig. 2. The EE mean Cmax and AUC24 values
for period 2 were higher than those for period 1 (p ≤ 0.019;
ANOVA). The NGMN Cmax and AUC24 were slightly lower
in period 2 than those in period 1 (p ≤ 0.043). For NG, no
significant differences were observed between treatments
(p ≥ 0.106). Relative bioavailability assessments for EE,
NGMN, and NG are presented in Table 3. Elagolix increased
EE Cmax and AUC by approximately 15% and 30%, respectively, reduced NGMN Cmax and AUC by approximately

Regimens
Period 1, day 21

Period 2, day 77

(ethinylestradiol/norgestimate 0.035
mg/0.25 mg QD alone) [n = 21]

(estradiol/norgestimate 0.035 mg/0.25
mg QD + elagolix 150 mg QD)
[n = 21]

0.168 ± 0.061
1.5 ± 0.5
1.27 ± 0.56
15.4 ± 5.7

0.195 ± 0.076c
1.9 ± 2.4
1.65 ± 0.72c
14.2 ± 4.9

2.29 ± 0.60
1.4 ± 0.3
18.3 ± 4.8
22.8 ± 7.3

2.00 ± 0.51c
1.4 ± 0.3
15.5 ± 4.3c
20.9 ± 6.8

3.02 ± 1.91
2.7 ± 4.9
51.6 ± 32.9
43.5 ± 24.6

2.72 ± 1.54
2.2 ± 2.5
49.0 ± 30.8
43.5 ± 24.8

–
–
–
–

504.4 ± 179.3
1.1 ± 0.4
1100.9 ± 392.6
3.7 ± 1.7

Cmax, maximum plasma concentration, Tmax time to maximum plasma concentration, AUC24 area under the
concentration–time curve from time zero to 24 h, t½ terminal elimination half-life, QD once daily, NGMN
norelgestromin, NG norgestrel, ANOVA analysis of variance
a

b
c
d

Harmonic mean ± pseudo-standard deviation; evaluations of t½ were based on statistical tests for β
N = 20 for t½ on day 77

Statistically significantly different from triphasic OC alone (ANOVA, p < 0.05)
N = 19
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Fig. 2  Pharmacokinetic profiles mean + standard deviation of triphasic OC alone and triphasic OC with elagolix (linear scale, n = 21). a Ethinylestradiol; b NGMN; c NG; and d Elagolix (n = 20). OC oral contraceptive, NGMN norelgestromin, NG norgestrel

Table 3  Relative bioavailability and 90% CIs in study 1
Regimens (test vs. reference)

PK parameter Central valuea
Test

Ethinylestradiol
Ethinylestradiol/norgestimate + elagolix vs. ethinylestradiol/norgestimate
alone
NGMN
Ethinylestradiol/norgestimate + elagolix vs. ethinylestradiol/norgestimate
alone
NG
Ethinylestradiol/norgestimate + elagolix vs. ethinylestradiol/norgestimate
alone

Relative bioavailability

Reference Point estimateb 90% CI

Cmax
AUC24

0.181 0.157
1.50 1.16

1.15
1.30

1.066–1.248
1.186–1.416

Cmax
AUC24

1.93
14.9

2.21
17.6

0.872
0.847

0.781–0.973
0.782–0.918

Cmax
AUC24

2.16
36.1

2.44
39.1

0.886
0.923

0.784–1.002
0.840–1.013

Units for Cmax and AUC24 central values are ng/mL and ng∙h/mL, respectively

Cmax maximum plasma concentration, AUC24 area under the concentration–time curve from time zero to 24 h, NGMN norelgestromin, NG norgestrel, CI confidence interval, PK pharmacokinetic
a

b

Antilogarithm of the least squares means for logarithms
Antilogarithm of the difference (test minus reference) of the least squares means for logarithms
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13% and 15%, respectively, and reduced NG by 11% and
8%, respectively. The EE Cmax and NG AUC24 90% CIs were
within the ‘no-effect boundary’ of 80–125% [10].
In study 2, the norethindrone PK parameters are shown
in Table 4 and the concentration–time profiles are shown in
Fig. 3. Other than an earlier mean Tmax value (p = 0.032), no
other norethindrone PK parameters were different between
the two periods.
Relative bioavailability assessments for EE, NGMN,
and NG are presented in Table 5. Elagolix decreased norethindrone Cmax and AUC by approximately 5% and 12%,
Table 4  Pharmacokinetic parameters of norethindrone
Pharmacokinetic
parameters (units)

Norethindrone
Cmax (ng/mL)
Tmax (h)
AUC24 (ng·h/mL)
t½a (h)
Elagolix
Cmax (ng/mL)
Tmax (h)
AUC24 (ng·h/mL)
t½a (h)

Regimens
Period 1

Period 2

(norethindrone
0.35 mg QD alone)
[n = 26]

(norethindrone 0.35 mg
QD + elagolix 150 mg
QD) [n = 26]

2.76 ± 0.88
1.67 ± 0.45
14.16 ± 5.89
7.85 ± 2.69
–
–
–
–

2.59 ± 0.76
1.44 ± 0.32b
12.30 ± 4.02
7.87 ± 3.51
555.4 ± 254.6
1.2 ± 0.4
1215.1 ± 540.6
3.8 ± 1.4

Cmax maximum plasma concentration, Tmax time to maximum plasma
concentration, AUC24 area under the concentration–time curve from
time zero to 24 h, t½ terminal elimination half-life, QD once daily,
ANOVA analysis of variance
a

Harmonic mean ± pseudo-standard deviation; evaluations of t½ were
based on statistical tests for β

b
Statistically significantly different from norethindrone alone
(ANOVA, p < 0.05)

respectively. The 90% CI for norethindrone Cmax was within
the no-effect boundary, whereas the lower bound of the
norethindrone AUC24 90% CI extended slightly below 0.80
(0.788) [10].
Elagolix PK parameters for both studies (Tables 2, 3) are
consistent with previously observed parameters [5, 8].

4.1 Pharmacodynamic Changes
Figures 4 and 5 show the mean concentration–time profiles
for FSH, LH, E2, and P in studies 1 and 2, respectively. In
study 1, when elagolix was coadministered with COCs, the
mean hormone exposure (assessed based on comparison of
AUC values in periods 1 and 2; n = 14) for FSH, LH, and
E2 appeared to be 31%, 38%, and 16% lower, respectively,
compared with those observed with COCs alone. As an
indirect marker of ovulation, 18% of women (4/22) had two
consecutive ovulatory P concentrations > 5 nmol/L on days
1–28 in period 1, and 14% of women (3/22) on days 57–84
in period 2.
In study 2, when elagolix was coadministered with norethindrone, the hormone exposure for FSH, LH, and P, was
similar to those observed with norethindrone alone. FSH and
LH concentrations were 10% higher and 8% lower (n = 19),
respectively, with coadministration when compared with
norethindrone alone. E2 concentrations appeared to be 32%
lower (n = 19) when elagolix was coadministered with norethindrone, compared with norethindrone alone. Sixty-one
percent of women (16/26) had two consecutive ovulatory P
concentrations on days 1–28 in period 1 and on days 57–84
in period 2.
For both studies, the observed interindividual variabilities
in hormone exposure (AUC) are overall larger than reported
for PK exposure, which may be explained by the sparse hormone sampling and large changes in hormone levels when
ovulation occurred.

Fig. 3  Pharmacokinetic profiles mean + standard deviation of the mini-pill alone and mini-pill with elagolix (linear scale, n = 26). a Norethindrone; b Elagolix
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Table 5  Relative bioavailability and 90% CIs in study 2
Regimens (test vs. reference)

Norethindrone
Norethindrone + elagolix vs. norethindrone alone

PK parameter

Cmax
AUC24

Central valuea

Relative bioavailability

Test

Reference

Point estimateb

90% CI

2.48
11.6

2.62
13.2

0.947
0.882

0.856−1.047
0.788−0.987

Units for Cmax and AUC24 central values are ng/mL and ng∙h/mL, respectively

Cmax maximum plasma concentration, AUC24 area under the concentration–time curve from time zero to 24 h, CIs confidence intervals, PK pharmacokinetic
a

b

Antilogarithm of the least squares means for logarithms
Antilogarithm of the difference (test minus reference) of the least squares means for logarithms

Fig. 4  Mean ± standard deviation concentration–time profiles after
administration of triphasic OC alone and triphasic OC with elagolix
in study 1 (linear scale, n = 22). Days 1–28, triphasic OC alone; days

57–84, triphasic OC with elagolix. a FSH; b LH; c estradiol; d progesterone. FSH follicle-stimulating hormone, LH luteinizing hormone

4.2 Safety and Tolerability

or elagolix were 6.5% (period 1, COC), 16.0% (period 2,
COC), and 24.0% (period 2, elagolix). The AEs in periods 1
and 2 were assessed as mild or moderate by the investigator,
except for one woman experiencing a single AE of tonsillitis
streptococcal (period 1), which was assessed as severe.
In study 2, 17/31 (54.8%) women experienced at least one
TEAE during period 2 (norethindrone + elagolix) compared
with 12/34 (35.3%) women during period 1 (norethindrone).
The most common TEAEs reported for two or more women
in period 2, in order of decreasing frequency, were headache,

In study 1, 10/31 (32.3%) women experienced at least one
TEAE during period 1 (COC) and 15/25 (60.0%) women
during period 2 (COC + elagolix). The most common
TEAEs reported for two or more women during period 1, in
order of decreasing frequency, were headache and upper respiratory tract infection (URTI), and headache, nausea, URTI,
and vomiting in period 2. The percentage of TEAEs assessed
by the investigator as possibly or probably related to COC
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Fig. 5.  Mean ± standard deviation concentration–time profiles after
administration of norethindrone alone and norethindrone with elagolix in study 1 (linear scale, n = 26). Days 1–28, norethindrone alone;

days 57–84, norethindrone with elagolix. a FSH; b LH; c estradiol; d
progesterone. FSH follicle-stimulating hormone, LH luteinizing hormone

nausea, URTI, increase in blood triglycerides, influenza, and
muscle spasms, and nausea, headache, breast tenderness, and
uterine spasm in period 1. The percentage of TEAEs assessed
by the investigator as possibly or probably related to norethindrone or elagolix were 26.5% (period 1, norethindrone),
19.4% (period 2, norethindrone), and 22.6% (period 2, elagolix). TEAEs were mostly assessed as mild to moderate for both
drugs; one woman experienced a single AE (increase in blood
triglycerides) assessed as severe during coadministration.
No deaths occurred during either study. No clinically significant vital signs, electrocardiogram, or changes in laboratory measurements were observed during study 1, and
during study 2 all other changes were unremarkable. The
regimens tested were generally well tolerated in both studies.

norethindrone) by 8–15%. The small but not clinically relevant reduction in progestin concentrations is attributed to
effects on the metabolic pathway of progestins [11–13].
Although the specific enzymes involved in progestin metabolism have not been well-defined, CYP3A4, CYP2B6, and uridine 5ʹ-diphospho (UDP)-glucuronosyltransferases may play
a role in the metabolism of norgestimate [14, 15], whereas
CYP3A and CYP2C19 enzymes also contribute to the metabolism of norethindrone [16–18]. Consistent with previous
findings where elagolix 150 mg once daily caused weak
induction of CYP3A [8], this study demonstrated that elagolix 150 mg once daily causes a small or negligible induction
of the metabolic pathways involved in progestin metabolism.
The half-lives of the progestins were not altered by elagolix
in this study, therefore the small impact by elagolix may be
mostly at the level of the gastrointestinal tract.
Administration of elagolix 150 mg once daily resulted
in a small increase in EE concentrations in study 1 (30%).
CYP3A enzymes, sulfation (SULT1E1), and glucuronidation (UGT1A1) have been reported to be involved in the
metabolism of EE [19–23]. Two previous studies support
that elagolix is a weak to moderate CYP3A inducer [1],
which indicates that elagolix coadministration may result

5 Discussion
Two DDI studies evaluated the effects of elagolix 150 mg
once daily on COCs in study 1 or the progestin-only oral
contraceptive in study 2. The PK results demonstrate that the
administration of elagolix 150 mg once daily slightly reduced
exposures of two progestins (norgestimate metabolites and
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in slightly lower, not higher, EE concentrations [8, 24, 25].
Because elagolix is a P-gp inhibitor and caused increases
in the exposure of the P-gp substrate digoxin [8], the small
increase in EE exposures observed in this study may be
attributed to inhibition of P-gp by elagolix and increase in
the absorption of EE. This is also supported by in vitro evidence suggesting that EE is a P-gp substrate [26].
Elagolix exposure and variability was comparable with
other phase I studies at the 150 mg once-daily dose [5, 8,
27]. Cross-study comparisons suggest that it does not appear
that either contraceptive affected elagolix PK.
These studies also evaluated the impact of coadministration of elagolix 150 mg once daily on the PD of hormonal
contraceptives. The studies demonstrate that coadministration of elagolix with hormonal oral contraceptives maintain the hormone suppressive profiles compared with oral
contraceptives administered alone. Hormonal contraceptives inhibit ovulation by inhibiting LH and FSH [9], which
then reduce E2 and P concentrations. Coadministration with
elagolix resulted in similar or lower LH and FSH exposures,
and ovulation rate (as assessed by P concentrations) did
not appear to be impacted in both studies. Therefore, the
coadministration of elagolix with hormonal contraceptives
may offer similar contraceptive effects to hormonal contraceptives administered alone. This is based on (1) small PK
changes in progestin (≤ 15%) and EE exposure (32%); (2)
similar or lower FSH, LH, and P PD profiles (with elagolix);
and (3) additional E2 suppression from elagolix in addition
to E2 suppression by hormonal contraceptives.
The overall safety and efficacy of the combinations of
elagolix and hormonal oral contraceptives needs to be further evaluated and confirmed in a larger study in women
with endometriosis-associated pain. Future studies should
determine if elagolix efficacy may be reduced when taking estrogen-containing contraceptives, and if the safety of
coadministration is maintained given the small increase in
EE concentrations that were observed in this study. The 30%
increase in EE concentrations are considered small for oral
contraceptives with low dose EE (< 25 μg); nevertheless,
one may need to take into consideration oral contraceptives
with a higher EE dose (> 25 μg).
The limitations of these studies include sparse hormone
sampling, and elagolix was only tested at the 150 mg dose.
Elagolix can be administered at the higher dose of 200 mg
twice daily. A future study may evaluate the PK/PD at the
higher elagolix dose.

6 Conclusion
Coadministration of elagolix with orally administered norethindrone or combination hormonal contraceptives containing EE and norgestimate resulted in small changes in the PK

of oral hormonal contraceptive components; elagolix PK do
not appear to be affected. The hormonal PD effects of oral
contraceptives were not negatively impacted by coadministration with elagolix.
Acknowledgements The authors thank AbbVie employees Keith Gordon, PhD, and Mohamad Shebley, PhD, for their contributions to the
review of the manuscript. They also thank Mia DeFino, MS, ELS,
a freelance medical writer under contract with AbbVie, for medical
writing support.

Declarations
Funding AbbVie funded the studies presented in this manuscript, and
was responsible for the study design, research, analysis, data collection, interpretation of data, and writing, reviewing, and approving of
the publication.
Conflict of interest Juki Ng, Yi-Lin Chiu, and Cheri E. Klein are employees of AbbVie, Inc., and may own stocks or stock options. Robert A. Feldman is an employee of the Baptist Health Medical Group
and was the principal investigator for these studies through Miami
Research Associates, LLC, where he received payment for his role in
leading the studies.
Ethics approval All studies were conducted in accordance with Good
Clinical Practice guidelines and the ethical principles that have their
origin in the Declaration of Helsinki. The protocols and informed consent forms were approved by the Ethics Committee or Institutional
Review Board at the site.
Consent to participate All participants provided written informed consent for participation in the studies.
Consent for publication Not applicable.
Data availability AbbVie is committed to responsible data sharing
regarding the clinical trials they sponsor. This includes access to
anonymized, individual and trial-level data (analysis data sets), as
well as other information (e.g. protocols and clinical study reports),
as long as the trials are not part of an ongoing or planned regulatory
submission. This includes requests for clinical trial data for unlicensed
products and indications. This clinical trial data can be requested by
any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a
research proposal and statistical analysis plan (SAP) and execution of
a data sharing agreement (DSA). Data requests can be submitted at any
time and the data will be accessible for 12 months, with possible extensions considered. For more information on the process, or to submit
a request, visit the following link: https://www.abbvie.com/our-scien
ce/c linic al-t rials/c linic al-t rials-d ata-a nd-i nform
 ation-s harin g/d ata-a nd-
information-sharing-with-qualified-researchers.html
Code availability Not applicable.
Author contributions All authors contributed to the study conception
and design and approval of the final content in the manuscript. JN and
CK contributed to material preparation, data collection and analysis.
Y-LC conducted the study designs, developed statistical methodology,
and oversaw the statistical analyses for both studies. RF was the principal investigator for both studies.

Elagolix and Oral Contraceptive DDI Studies
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any
non-commercial use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other
third party material in this article are included in the article’s Creative
Commons licence, unless indicated otherwise in a credit line to the
material. If material is not included in the article’s Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission
directly from the copyright holder. To view a copy of this licence, visit
http://creativecommons.org/licenses/by-nc/4.0/.

References
1. AbbVie Inc. Prescribing information for Orlissa (elagolix). North
Chicago: AbbVie Inc.; 2018.
2. Surrey E, Taylor HS, Giudice L, Lessey BA, Abrao MS, Archer
DF, et al. Long-term outcomes of elagolix in women with endometriosis: results from two extension studies. Obstet Gynecol.
2018;132(1):147–60. https://doi.org/10.1097/aog.0000000000
002675.
3. Surrey ES, Soliman AM, Palac HL, Agarwal SK. Impact of elagolix on workplace and household productivity among women with
moderate to severe pain associated with endometriosis: a pooled
analysis of two phase III trials. Patient. 2019;12(6):651–60.
https://doi.org/10.1007/s40271-019-00394-7.
4. Pokrzywinski RM, Soliman AM, Chen J, Snabes M, Diamond
MP, Surrey E, et al. Impact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two
phase III clinical trials. Fertil Steril. 2019;112(3):545–51. https://
doi.org/10.1016/j.fertnstert.2019.04.031.
5. Ng J, Chwalisz K, Carter DC, Klein CE. Dose-dependent suppression of gonadotropins and ovarian hormones by elagolix
in healthy premenopausal women. J Clin Endocrinol Metab.
2017;102(5):1683–91. https://doi.org/10.1210/jc.2016-3845.
6. Dun EC, Taylor HS. Elagolix: a promising oral GnRH antagonist
for endometriosis-associated pain. Oncotarget. 2017;8(59):99219–
20. https://doi.org/10.18632/oncotarget.22381.
7. Archer DF, Ng J, Chwalisz K, Chiu YL, Feinberg EC, Miller CE,
et al. Elagolix suppresses ovulation in a dose-dependent manner:
results from a 3-month, randomized study in ovulatory women. J
Clin Endocrinol Metab. 2020;105(3):dgz086. https://doi.org/10.
1210/clinem/dgz086.
8. Shebley M, Polepally AR, Nader A, Ng JW, Winzenborg I, Klein
CE, et al. Clinical pharmacology of elagolix: an oral gonadotropin-releasing hormone receptor antagonist for endometriosis. Clin
Pharmacokinet. 2020;59(3):297–309. https://doi.org/10.1007/
s40262-019-00840-7.
9. Rivera R, Yacobson I, Grimes D. The mechanism of action of
hormonal contraceptives and intrauterine contraceptive devices.
Am J Obstet Gynecol. 1999;181(5 Pt 1):1263–9. https://doi.org/
10.1016/s0002-9378(99)70120-1.
10. US Department of Health and Human Services. Guidance for
industry: in vitro metabolism- and transporter-mediated drug-drug
interaction studies. 2017. https://www.fda.gov/downloads/Drugs/
Guidances/UCM581965.pdf. 2017.
11. Gupta C, Osterman J, Miljkovic M, Bardin CW. The in vivo
metabolism of progestins. IV. The metabolic clearance rate and
plasma binding of 6alpha-methylpregn-4-ene-3, 20-dione in
women. Steroids. 1977;29(5):669–77. https://doi.org/10.1016/
0039-128x(77)90018-6.

12. Sitruk-Ware R, Nath A. Characteristics and metabolic effects of
estrogen and progestins contained in oral contraceptive pills. Best
Pract Res Clin Endocrinol Metab. 2013;27(1):13–24. https://doi.
org/10.1016/j.beem.2012.09.004.
13. Zhang N, Shon J, Kim MJ, Yu C, Zhang L, Huang SM, et al.
Role of CYP3A in oral contraceptives clearance. Clin Transl Sci.
2018;11(3):251–60. https://doi.org/10.1111/cts.12499.
14. Hammond GL, Abrams LS, Creasy GW, Natarajan J, Allen JG,
Siiteri PK. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception. 2003;67(2):93–9. https://doi.org/10.1016/s0010-7824(02)
00473-0.
15. Ahire D, Sinha S, Brock B, Iyer R, Mandlekar S, Subramanian M.
Metabolite identification, reaction phenotyping, and retrospective
drug-drug interaction predictions of 17-deacetylnorgestimate, the
active component of the oral contraceptive norgestimate. Drug
Metab Dispos. 2017;45(6):676–85. https://doi.org/10.1124/dmd.
116.073940.
16. Schoonen WG, Deckers GH, de Gooijer ME, de Ries R, Kloosterboer HJ. Hormonal properties of norethisterone, 7alpha-methylnorethisterone and their derivatives. J Steroid Biochem Mol Biol.
2000;74(4):213–22. https://doi.org/10.1016/s0960-0 760(00)
00125-4.
17. Stanczyk FZ, Roy S. Metabolism of levonorgestrel, norethindrone, and structurally related contraceptive steroids. Contraception. 1990;42(1):67–96. https://doi.org/10.1016/0010-7824(90)
90093-b.
18. Korhonen T, Turpeinen M, Tolonen A, Laine K, Pelkonen O.
Identification of the human cytochrome P450 enzymes involved
in the in vitro biotransformation of lynestrenol and norethindrone.
J Steroid Biochem Mol Biol. 2008;110(1–2):56–66. https://doi.
org/10.1016/j.jsbmb.2007.09.025.
19. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The
involvement of CYP3A4 and CYP2C9 in the metabolism of 17
alpha-ethinylestradiol. Drug Metab Dispos. 2004;32(11):1209–12.
https://doi.org/10.1124/dmd.104.000182.
20. Bolt WH, Kappus H, Bolt HM. Ring A oxidation of 17alphaethynylestradiol in man. Horm Metab Res. 1974;6(5):432. https://
doi.org/10.1055/s-0028-1095729.
21. Guengerich FP. Oxidation of 17 alpha-ethynylestradiol by human
liver cytochrome P-450. Mol Pharmacol. 1988;33(5):500–8.
22. Schrag ML, Cui D, Rushmore TH, Shou M, Ma B, Rodrigues AD.
Sulfotransferase 1E1 is a low km isoform mediating the 3-O-sulfation of ethinyl estradiol. Drug Metab Dispos. 2004;32(11):1299–
303. https://doi.org/10.1124/dmd.32.11.
23. Yasuda S, Suiko M, Liu MC. Oral contraceptives as substrates and inhibitors for human cytosolic SULTs. J Biochem.
2005;137(3):401–6. https://doi.org/10.1093/jb/mvi047.
24. Elagolix Multidiscipline Review, US FDA Center for Drug Evaluation and Research. 2018. https://www.accessdata.fda.gov/drugs
atfda_docs/nda/2018/210450Orig1s000MultiD.pdf. Accessed 17
Jan 2020.
25. Polepally AR, Dufek MB, Dharia SP, Kamradt K, Lin J, Peloso
PM, et al. Drug-drug interaction with midazolam with elagolix,
a novel oral GnRH antagonist: analyses of data from two studies.
Clin Pharmacol Drug Dev. 2017;6:48.
26. Kim WY, Benet LZ. P-glycoprotein (P-gp/MDR1)-mediated
efflux of sex-steroid hormones and modulation of P-gp expression in vitro. Pharm Res. 2004;21(7):1284–93. https://doi.org/10.
1023/b:pham.0000033017.52484.81.
27. Ng J, Duan WR, Marbury T, Schmidt JM, Klein CE. Elagolix
pharmacokinetic profiles in women with renal or hepatic impairment. Clin Pharmacol Drug Dev. 2019;8(8):1053–61. https://doi.
org/10.1002/cpdd.640.

